{"590061":{"#nid":"590061","#data":{"type":"event","title":"PhD Defense bt Vitor Kamada","body":[{"value":"\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EPh.D. Dissertation Defense \u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EVitor Kamada\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003ETitle:\u003C\/strong\u003E Innovation in the Biopharmaceutical Industry\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EAbstract:\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003EThree aspects of the drug development process are little understood in the literature: 1) which type of organization has comparative advantage in conducting clinical trials, firms or nonprofit organization (NPOs)?; 2) what determines the timing of technological collaboration, a step usually far away from drug commercialization?; and 3) how the strategies making, allying, and buying R\u0026amp;D impact the probability of drug approval? Using data on over 20,000 clinical trials, 800 technological alliances, and 14,000 R\u0026amp;D projects, the main findings of this econometric study are: 1) firms complete each phase of clinical trial faster than nonprofit organizations; 2) licensor scientific and technological specialization is the main factor to speed up the technological collaboration; and 3) R\u0026amp;D projects developed by research alliance have higher probability of drug approval than internal R\u0026amp;D projects, but R\u0026amp;D projects originated from M\u0026amp;A have lower probability of drug approval than internal R\u0026amp;D projects. Together these findings inform policy makers and managers on how to foster the innovation performance in the biopharmaceutical industry.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003ECommittee:\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003EDr. Usha Nair-Reichert, Chair, Advisor, School of Economics -Georgia Institute of Technology\u003C\/p\u003E\r\n\r\n\u003Cp\u003EDr. Levent Kutlu, School of Economics -Georgia Institute of Technology \/ Antalya International University\u003C\/p\u003E\r\n\r\n\u003Cp\u003EDr. Patrick S. McCarthy, School of Economics -Georgia Institute of Technology\u003C\/p\u003E\r\n\r\n\u003Cp\u003EDr. Mikhail Klimenko, School of Economics -Georgia Institute of Technology\u003C\/p\u003E\r\n\r\n\u003Cp\u003EDr.\u0026nbsp; Richard Barke, School of Public Policy -Georgia Institute of Technology\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EDate\/Time:\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003EWednesday, April 26, 2017, 2:00 to 3:30 pm.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003ELocation:\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003EOld CE Building, Room 204.\u003C\/p\u003E\r\n","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":"","field_summary_sentence":[{"value":"Innovation in the Biopharmaceutical Industry"}],"uid":"27707","created_gmt":"2017-04-07 20:47:49","changed_gmt":"2017-04-07 20:49:57","author":"Tatianna Richardson","boilerplate_text":"","field_publication":"","field_article_url":"","field_event_time":{"event_time_start":"2017-04-26T15:00:00-04:00","event_time_end":"2017-04-26T17:00:00-04:00","event_time_end_last":"2017-04-26T17:00:00-04:00","gmt_time_start":"2017-04-26 19:00:00","gmt_time_end":"2017-04-26 21:00:00","gmt_time_end_last":"2017-04-26 21:00:00","rrule":null,"timezone":"America\/New_York"},"extras":[],"groups":[{"id":"221981","name":"Graduate Studies"}],"categories":[],"keywords":[{"id":"100811","name":"Phd Defense"}],"core_research_areas":[],"news_room_topics":[],"event_categories":[{"id":"1788","name":"Other\/Miscellaneous"}],"invited_audience":[{"id":"78771","name":"Public"}],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[],"email":[],"slides":[],"orientation":[],"userdata":""}}}